Related Experiment Videos

Increased clopidogrel response is associated with ABCC3 expression: a pilot study

André Ducati Luchessi1, Vivian Nogueira Silbiger, Alvaro Cerda

  • 1Faculty of Pharmaceutical Science, Department of Clinical and Toxicological Analyses, University of Sao Paulo, Sao Paulo, Brazil. adluchessi@usp.br

Clinica Chimica Acta; International Journal of Clinical Chemistry
|November 2, 2011
PubMed

Insights

Low ABCC3 gene expression in peripheral blood cells is linked to a better response to clopidogrel treatment in coronary artery disease patients. Further research is needed to understand this clopidogrel-ABCC3 relationship.

Area of Science:

  • Pharmacogenomics
  • Cardiovascular Medicine
  • Molecular Biology

Background:

  • Coronary artery disease (CAD) patients often receive clopidogrel, but responses vary.
  • Gene expression, specifically ABCB1 and ABCC3, may influence clopidogrel efficacy.
  • Investigating these genetic markers can optimize antiplatelet therapy.

Purpose of the Study:

  • To examine the association between ABCB1 and ABCC3 gene expression in peripheral blood cells (PBC) and clopidogrel response in CAD patients.
  • To determine if genetic variations predict treatment outcomes.

Main Methods:

  • Twenty-six male CAD patients (50-70 years) on clopidogrel therapy were studied.
  • Platelet reactivity was measured using P2Y12 Reaction Units (PRU).
  • ABCB1 and ABCC3 mRNA expression levels in PBC were quantified via qPCR.

Main Results:

  • A significant association was found between ABCC3 expression and clopidogrel response.
  • Higher ABCC3 expression correlated with reduced clopidogrel efficacy (1.7 times more expressed in non-responders).
  • Low ABCC3 mRNA expression (Qe1) significantly increased the likelihood of a good clopidogrel response (OR: 18.00, p=0.001).

Conclusions:

  • Reduced ABCC3 mRNA expression in PBC is a potential biomarker for enhanced clopidogrel response in CAD.
  • The functional role of ABCC3 in clopidogrel metabolism and action requires further investigation.
Abstract

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...